Shanghai Fosun Pharmaceutical's subsidiary FXS0683 tablet has been approved for clinical trials.

Shanghai Fosun Pharmaceutical (600196.SH) announced that its subsidiary, Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. (referred to as "Shanghai Fosun Pharmaceutical Industrial"), has received approval from the National Medical Products Administration to conduct clinical trials for FXS0683 in the treatment of hematologic malignancies. Shanghai Fosun Pharmaceutical Industrial plans to conduct Phase I clinical studies for FXS0683 in China once the necessary conditions are met. FXS0683 is an orally-administered small molecule innovative drug developed independently by the group. It is a potent and highly selective new generation Bcl-2 inhibitor intended for the treatment of hematologic malignancies. FXS0683 works by targeting and inhibiting the activity of wild-type and mutant Bcl-2 proteins, promoting apoptosis in tumor cells and inhibiting tumor cell proliferation and tumor tissue growth.